Status:
COMPLETED
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Lead Sponsor:
The Cleveland Clinic
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Polycystic Kidney Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression block...
Detailed Description
This study is a prospective, randomized,open label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocki...
Eligibility Criteria
Inclusion
- ADPKD
- \> 18 y.o. GFR greater than or equal to 25. Willingness to be randomized to any treatment group Willingness to follow protocol requirements-frequent testing and follow-up required at Cleveland Clinic(Cleveland, OH) signed informed consent Willingness to use birth control(male and female)
Exclusion
- Pregnancy
- post partum
- lactating
- system illness with renal involvement
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00286156
Start Date
October 1 2006
End Date
December 1 2014
Last Update
April 6 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cleveland Clinic- main campus
Cleveland, Ohio, United States, 44195